Cargando…
Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
Stem cell antigen-1 (Sca-1) is used to isolate and characterize tumor initiating cell populations from tumors of various murine models [1]. Sca-1 induced disruption of TGF-β signaling is required in vivo tumorigenesis in breast cancer models [2, 3-5]. The role of human Ly6 gene family is only beginn...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905465/ https://www.ncbi.nlm.nih.gov/pubmed/26862846 http://dx.doi.org/10.18632/oncotarget.7163 |
_version_ | 1782437266069651456 |
---|---|
author | Luo, Linlin McGarvey, Peter Madhavan, Subha Kumar, Rakesh Gusev, Yuriy Upadhyay, Geeta |
author_facet | Luo, Linlin McGarvey, Peter Madhavan, Subha Kumar, Rakesh Gusev, Yuriy Upadhyay, Geeta |
author_sort | Luo, Linlin |
collection | PubMed |
description | Stem cell antigen-1 (Sca-1) is used to isolate and characterize tumor initiating cell populations from tumors of various murine models [1]. Sca-1 induced disruption of TGF-β signaling is required in vivo tumorigenesis in breast cancer models [2, 3-5]. The role of human Ly6 gene family is only beginning to be appreciated in recent literature [6-9]. To study the significance of Ly6 gene family members, we have visualized one hundred thirty gene expression omnibus (GEO) dataset using Oncomine (Invitrogen) and Georgetown Database of Cancer (G-DOC). This analysis showed that four different members Ly6D, Ly6E, Ly6H or Ly6K have increased gene expressed in bladder, brain and CNS, breast, colorectal, cervical, ovarian, lung, head and neck, pancreatic and prostate cancer than their normal counter part tissues. Increased expression of Ly6D, Ly6E, Ly6H or Ly6K was observed in sub-set of cancer type. The increased expression of Ly6D, Ly6E, Ly6H and Ly6K was found to be associated with poor outcome in ovarian, colorectal, gastric, breast, lung, bladder or brain and CNS as observed by KM plotter and PROGgeneV2 platform. The remarkable findings of increased expression of Ly6 family members and its positive correlation with poor outcome on patient survival in multiple cancer type indicate that Ly6 family members Ly6D, Ly6E, Ly6K and Ly6H will be an important targets in clinical practice as marker of poor prognosis and for developing novel therapeutics in multiple cancer type. |
format | Online Article Text |
id | pubmed-4905465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-49054652016-06-24 Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome Luo, Linlin McGarvey, Peter Madhavan, Subha Kumar, Rakesh Gusev, Yuriy Upadhyay, Geeta Oncotarget Research Paper Stem cell antigen-1 (Sca-1) is used to isolate and characterize tumor initiating cell populations from tumors of various murine models [1]. Sca-1 induced disruption of TGF-β signaling is required in vivo tumorigenesis in breast cancer models [2, 3-5]. The role of human Ly6 gene family is only beginning to be appreciated in recent literature [6-9]. To study the significance of Ly6 gene family members, we have visualized one hundred thirty gene expression omnibus (GEO) dataset using Oncomine (Invitrogen) and Georgetown Database of Cancer (G-DOC). This analysis showed that four different members Ly6D, Ly6E, Ly6H or Ly6K have increased gene expressed in bladder, brain and CNS, breast, colorectal, cervical, ovarian, lung, head and neck, pancreatic and prostate cancer than their normal counter part tissues. Increased expression of Ly6D, Ly6E, Ly6H or Ly6K was observed in sub-set of cancer type. The increased expression of Ly6D, Ly6E, Ly6H and Ly6K was found to be associated with poor outcome in ovarian, colorectal, gastric, breast, lung, bladder or brain and CNS as observed by KM plotter and PROGgeneV2 platform. The remarkable findings of increased expression of Ly6 family members and its positive correlation with poor outcome on patient survival in multiple cancer type indicate that Ly6 family members Ly6D, Ly6E, Ly6K and Ly6H will be an important targets in clinical practice as marker of poor prognosis and for developing novel therapeutics in multiple cancer type. Impact Journals LLC 2016-02-03 /pmc/articles/PMC4905465/ /pubmed/26862846 http://dx.doi.org/10.18632/oncotarget.7163 Text en Copyright: © 2016 Luo et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Luo, Linlin McGarvey, Peter Madhavan, Subha Kumar, Rakesh Gusev, Yuriy Upadhyay, Geeta Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title_full | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title_fullStr | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title_full_unstemmed | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title_short | Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome |
title_sort | distinct lymphocyte antigens 6 (ly6) family members ly6d, ly6e, ly6k and ly6h drive tumorigenesis and clinical outcome |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905465/ https://www.ncbi.nlm.nih.gov/pubmed/26862846 http://dx.doi.org/10.18632/oncotarget.7163 |
work_keys_str_mv | AT luolinlin distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome AT mcgarveypeter distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome AT madhavansubha distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome AT kumarrakesh distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome AT gusevyuriy distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome AT upadhyaygeeta distinctlymphocyteantigens6ly6familymembersly6dly6ely6kandly6hdrivetumorigenesisandclinicaloutcome |